Investment thesis
Early-stage advanced therapies: cell therapy, gene therapy, RNA-based therapy, targeted therapies and microbiome-based treatments
Sesamers tracks 3 portfolio companies across 3 rounds, 3 of them as lead investor. Its most recent tracked deal: Oyster Therapeutics, Nov 2026.
Portfolio
Past investments
| Company | Round | Role | Date | Round size |
|---|---|---|---|---|
| Oyster Therapeutics London, United Kingdom Read the announcement → | Series A | Lead | Nov 2026 | €54.1M |
| Undecimal Bio Cambridge, United Kingdom Read the announcement → | Seed | Lead | Oct 2026 | €16M |
| Aptadir Therapeutics Milan, Italy Read the announcement → | Seed | Lead | Sep 2026 | €40M |